Cash receipts heading the wrong direction, cash burn heading in the wrong direction. I hope they can start to sell some of the new products they are bringing to the market, without further delays.
Need to see some of this happening for CDX "Michael was responsible for the growth of the pharmaceutical and cardiology device sales division from $100K to US$65M under his leadership."
Starting to think this is another small cap gem, "all talk and no trousers".
Add to My Watchlist
What is My Watchlist?
